A Phase III 2 Arms, Multicenter, Randomised, Double-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo

Trial Profile

A Phase III 2 Arms, Multicenter, Randomised, Double-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Ozenoxacin (Primary)
  • Indications Impetigo
  • Focus Registrational; Therapeutic Use
  • Sponsors Ferrer
  • Most Recent Events

    • 13 Jun 2018 Results published in the JAMA Dermatology.
    • 14 Dec 2017 Results presented in a Medimetriks Pharmaceuticals media release.
    • 14 Dec 2017 According to a Medimetriks Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) approved Xepi (ozenoxacin) Cream, 1% for the treatment of impetigo in patients two months of age and older when applied topically twice daily for 5 days. Based on the data from this and other trial (see profile 202934).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top